We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Original Investigation |

Risks and Benefits Associated With Prestroke Antiplatelet Therapy Among Patients With Acute Ischemic Stroke Treated With Intravenous Tissue Plasminogen Activator

Ying Xian, MD, PhD1; Jerome J. Federspiel, MD, PhD2,3; Maria Grau-Sepulveda, MD, MPH1; Adrian F. Hernandez, MD, MHS1; Lee H. Schwamm, MD4; Deepak L. Bhatt, MD, MPH5; Eric E. Smith, MD, MPH6,7; Mathew J. Reeves, PhD8; Laine Thomas, PhD1; Laura Webb, MS1; Janet Prvu Bettger, ScD1; Daniel T. Laskowitz, MD, MHS9; Gregg C. Fonarow, MD10; Eric D. Peterson, MD, MPH1
[+] Author Affiliations
1Duke Clinical Research Institute, Durham, North Carolina
2medical student at University of North Carolina School of Medicine, Chapel Hill
3currently with Department of Gynecology and Obstetrics, Johns Hopkins School of Medicine, Baltimore, Maryland
4Division of Neurology, Massachusetts General Hospital, Boston
5Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston, Massachusetts
6Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
7Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada
8Department of Epidemiology, Michigan State University, East Lansing
9Department of Neurology, Duke University Medical Center, Durham, North Carolina
10Division of Cardiology, University of California, Los Angeles
JAMA Neurol. 2016;73(1):50-59. doi:10.1001/jamaneurol.2015.3106.
Text Size: A A A
Published online

Importance  Intravenous tissue plasminogen activator (tPA) is known to improve outcomes in ischemic stroke; however, many patients may have been receiving antiplatelet therapy before acute ischemic stroke and could face an increased risk for bleeding when treated with tPA.

Objective  To assess the risks and benefits associated with prestroke antiplatelet therapy among patients with ischemic stroke who receive intravenous tPA.

Design, Setting, and Participants  This observational study used data from the American Heart Association and American Stroke Association Get With the Guidelines–Stroke registry, which included 85 072 adult patients with ischemic stroke who received intravenous tPA in 1545 registry hospitals from January 1, 2009, through March 31, 2015. Data were analyzed during the same period.

Exposures  Prestroke antiplatelet therapy before tPA administration for acute ischemic stroke.

Main Outcomes and Measures  Symptomatic intracranial hemorrhage (sICH), in-hospital mortality, discharge ambulatory status, and modified Rankin Scale score (range, 0 [no symptoms] to 6 [death]).

Results  Of the 85 072 registry patients, 38 844 (45.7%) were receiving antiplatelet therapy before admission; 46 228 patients (54.3%) were not. Patients receiving antiplatelet therapy were older (median [25th-75th percentile] age, 76 [65-84] vs 68 [56-80] years) and had a higher prevalence of cardiovascular risk factors. The unadjusted rate of sICH was higher in patients receiving antiplatelet therapy (5.0% vs 3.7%). After risk adjustment, prior use of antiplatelet agents remained associated with higher odds of sICH compared with no use (adjusted odds ratio [AOR], 1.18 [95% CI, 1.10-1.28]; absolute difference, +0.68% [95% CI, 0.36%-1.01%]; number needed to harm [NNH], 147). Among patients enrolled on October 1, 2012, or later, the highest odds (95% CIs) of sICH were found in 15 116 patients receiving aspirin alone (AOR, 1.19 [1.06- 1.34]; absolute difference [95% CI], +0.68% [0.21%-1.20%]; NNH, 147) and 2397 patients receiving dual antiplatelet treatment of aspirin and clopidogrel (AOR, 1.47 [1.16-1.86]; absolute difference, +1.67% [0.58%-3.00%]; NNH, 60). The risk for in-hospital mortality was similar between those who were and were not receiving antiplatelet therapy after adjustment (8.0% vs 6.6%; AOR, 1.00 [0.94-1.06]; nonsignificant absolute difference, −0.01% [−0.37% to 0.36%]). However, patients receiving antiplatelet therapy had a greater risk-adjusted likelihood of independent ambulation (42.1% vs 46.6%; AOR, 1.13 [1.08-1.17]; absolute difference, +2.23% [1.55%-2.92%]; number needed to treat, 43) and better functional outcomes (modified Rankin Scale score, 0-1) at discharge (24.1% vs 27.8%; AOR, 1.14; 1.07-1.22; absolute difference, +1.99% [0.78%-3.22%]; number needed to treat, 50).

Conclusions and Relevance  Among patients with an acute ischemic stroke treated with intravenous tPA, those receiving antiplatelet therapy before the stroke had a higher risk for sICH but better functional outcomes than those who were not receiving antiplatelet therapy.

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?


Place holder to copy figure label and caption
Figure 1.
Study Population

INR indicates international normalized ratio; GWTG-Stroke, American Heart Association and American Stroke Association Get With the Guidelines–Stroke program; and tPA, tissue plasminogen activator.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
Preadmission Antiplatelet Therapy and Symptomatic Intracranial Hemorrhage (sICH)

Data are given overall and in clinically relevant subgroups. AOR indicates adjusted odds ratio; CAD, coronary artery disease; MI, myocardial infarction; and TIA, transient ischemic attack.

aIncludes patients admitted October 1, 2012, or later.

Graphic Jump Location




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles

Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice, 3rd ed
Matching Content and Context: Evidence-Based Teaching Scripts

Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice, 3rd ed
Verbal Synopses